CVS Corp (CVS) 103.45 $CVS Cardinal Health Set to Buy

New Post Public Reply Private Reply Replies (0) Message Board

Mar 3, 2015 at 7:58 PM

CVS Corp (CVS) 103.45 $CVS

Cardinal Health Set to Buy Cordis, Shares Hit 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 10:26AM CST
Cardinal Health Inc. (CAH) hit a 52-week high of $90.49 on Mar 2, 2015, after the company announced plans to acquire Cordis, a unit of Johnson & Johnson (JNJ).
JNJ: 102.34 (-0.88), CAH: 88.43 (-1.09), CVS: 103.45 (-0.74), HSIC: 140.77 (-1.11)

Horizon Pharma Soars On Q4 Beat, Guidance Raise
at Investor's Business Daily - Fri Feb 27, 10:48AM CST
Specialty drugmaker Horizon Pharma (HZNP) beat analysts' Q4 expectations and raised its 2015 guidance Friday, sending its stock up 10% to a new high. Horizon's revenue in the quarter more than tripled to $103.8 million, about $8 million above...
ESRX: 84.35 (-0.58), AZN: 68.28 (-0.45), HZNP: 20.97 (+0.46), CVS: 103.45 (-0.74)

Catamaran EPS Tops, But Stock Falls On Weak Guidance
at Investor's Business Daily - Thu Feb 26, 10:59AM CST
Catamaran (CTRX) surpassed fourth-quarter earnings and sales estimates on Thursday, but shares sank on its weak full-year EPS outlook. The provider of pharmacy benefit management services saw adjusted earnings climb 19.6% to 67 cents a share in Q4,...
ESRX: 84.35 (-0.58), CTRX: 49.67 (-0.62), BRLI: 35.20 (-0.10), AAC: 30.73 (-3.54), CVS: 103.45 (-0.74), RAD: 8.10 (-0.06)

Impeccable Quality But There Are No Bargains Today In The S&P 500 Consumer Staples Sector: Part 8
Chuck Carnevale - at Seeking Alpha - Wed Feb 25, 11:00AM CST

WFM: 55.53 (-0.69), KO: 42.95 (-0.25), DPS: 78.99 (-0.21), PM: 82.70 (-0.25), AVP: 8.82 (-0.04), MKC: 75.25 (-0.15), CAG: 34.96 (-0.14), CVS: 103.45 (-0.74), COST: 147.37 (-0.57), PG: 85.16 (-0.25), GIS: 53.48 (-0.02), BF.B: 91.21 (-0.67)

Billions on the Line in the Next Drug Pricing War
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 24, 7:02AM CST
Source: Gilead Sciences One win whets the appetite for another. That certainly seems to be the case for the nation's two largest pharmacy benefits managers, Express Scripts and CVS Health . After scoring a victory in bringing hepatitis C...
ESRX: 84.35 (-0.58), GILD: 102.79 (-1.04), CVS: 103.45 (-0.74), REGN: 412.50 (-5.94)

$20 Billion Market: What’s the Best Stock to Buy?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Fri Feb 20, 7:01AM CST
Modern drugs, known as "biologics," are harder to develop and harder to replicate than the conventional small molecule medications we all grew up with. As a result, competitors have to work harder to develop generic approximations of them, known as...
ESRX: 84.35 (-0.58), MRK: 58.34 (-0.24), PFE: 34.56 (-0.21), MYL: 55.44 (-2.45), CVS: 103.45 (-0.74), AMGN: 158.56 (-1.07), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84), HSP: 87.71 (+0.04), NVS: 99.06 (-1.01)

Oil Price Collapse Gives Patient Investors a Convenient Excuse to Buy
Rich Duprey, The Motley Fool - Motley Fool - Thu Feb 19, 8:02AM CST
It feels so 2008 with gas prices below $2.00 a gallon, and it creates a convenient time for investors to profit. Photo: Flickr via Minale Tattersfield. You have to go back to the depths of the Great Recession to find gasoline prices as...
MPC: 102.77 (+0.99), MCD: 99.74 (-0.26), CVS: 103.45 (-0.74), BKW: 35.50 (-1.16)

At Least Highly Rated Retailers Click With Consumers
at Investor's Business Daily - Wed Feb 18, 7:02AM CST
When it came to customer satisfaction ratings, the nation's retailers capped 2014 on a sour note. In the last quarter of 2014, customer satisfaction was down for the first time in four years, according to a report that the American Customer...
WFM: 55.53 (-0.69), AMZN: 384.61 (-1.04), HD: 116.07 (-0.05), M: 63.47 (-0.43), WMT: 83.37 (-0.59), FDO: 78.66 (-0.13), RAD: 8.10 (-0.06), NFLX: 474.71 (-5.54), LB: 91.28 (-1.16), DLTR: 79.16 (-0.76), WBA: 83.21 (-0.41), TGT: 78.00 (+0.32), CVS: 103.45 (-0.74), COST: 147.37 (-0.57), JWN: 79.97 (-0.71), DG: 71.65 (-1.44), LOW: 75.01 (-0.08)

Jim Cramer's 'Mad Money' Recap: What's Hot and Fashionable in Stocks
at The Street - Tue Feb 17, 7:26PM CST
Cyber security stocks are among those every portfolio should have, Cramer says.
LMT: 199.93 (-3.09), UNH: 112.86 (-1.54), SKX: 68.45 (+0.18), NGHC: 18.79 (-0.02), INTC: 34.10 (+0.04), PANW: 148.90 (+2.92), JACK: 97.43 (-1.07), RPTP: 9.61 (-0.07), COST: 147.37 (-0.57), LOW: 75.01 (-0.08), REGN: 412.50 (-5.94), TRV: 107.40 (-0.50), CY: 15.16 (-0.24), MU: 29.66 (-1.58), FEYE: 45.07 (+0.25), ETH: 26.75 (-0.84), BRCM: 45.43 (-0.76), VFC: 76.69 (-0.55), EW: 134.58 (-1.27), COLM: 56.39 (+0.04), SMH: 57.51 (-0.96), FIVE: 31.41 (-0.34), WM: 55.18 (+0.33), PCLN: 1,242.03 (-7.37), HAIN: 62.34 (+0.01), CVS: 103.45 (-0.74), JWN: 79.97 (-0.71), FTNT: 34.03 (-0.07)

Surprise! We Still Need Drugmakers to Develop Revolutionary Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 17, 10:02AM CST
Source: Gilead Sciences. All of the market's chatter surrounding Gilead Sciences ' and AbbVie 's hepatitis C drugs this past year may have you thinking that these companies have won the decades long battle against this tough-to-treat disease....
VRTX: 123.52 (+3.35), GILD: 102.79 (-1.04), CVS: 103.45 (-0.74), ABBV: 59.62 (-0.84)

CVS Health Raises Concerns about the Potential Impact of New Class of Cholesterol Drugs on the Health Care System
PR Newswire - Tue Feb 17, 8:00AM CST
CVS Health (NYSE: CVS) weighs in on the next chapter in the debate about the impact of expensive drugs on the health care system in a commentary that appears today on the Health Affairs blog. Currently in development, PCSK9 (proprotein convertase subtilisin/kexin 9) enzyme inhibitors could successfully treat millions of Americans with high cholesterol, but at great cost to the health care system. The authors describe the real challenge is not the cost per dose, but the large eligible patient population and the duration of chronic treatment, which could span decades.
CVS: 103.45 (-0.74)

CVS Health To Present At RBC Capital Markets Healthcare Conference
PR Newswire - Mon Feb 16, 11:20AM CST
CVS Health Corporation (NYSE: CVS) today announced that Dave Denton, executive vice president and chief financial officer, will be speaking to investors at the RBC Capital Markets Healthcare Conference on February 25, 2015, at approximately 10:00 a.m. ET.
CVS: 103.45 (-0.74)

Did Rite Aid Corporation Just Ink a Super-Smart Deal?
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 16, 8:03AM CST
Source: Wiki Commons user Specious. In order to overcome headwinds from slowing sales and sky-high debt, Rite Aid has been closing stores and sweet-talking lenders for years. The pharmacy operator's recently announced acquisition of...
ESRX: 84.35 (-0.58), WBA: 83.21 (-0.41), CVS: 103.45 (-0.74), RAD: 8.10 (-0.06)

What Can 2014 Results Tell Us About The Future For CVS Health?
David Schauber, Jr. - at Seeking Alpha - Mon Feb 16, 2:09AM CST

CVS: 103.45 (-0.74)

How Did a Janitor Amass $8 Million? The Same Way You Can
Selena Maranjian, The Motley Fool - Motley Fool - Sun Feb 15, 7:03PM CST
Brattleboro, Vermont, will be even nicer than it already is, thanks to Ronald Read. Photo: Ken Gallager The name Ronald Read might not mean too much to you -- yet -- but it certainly does to Vermont's Brooks Memorial Library and Brattleboro...
T: 34.41 (-0.23), GE: 25.86 (-0.25), DE: 91.27 (+0.24), GM: 37.80 (+0.19), CVS: 103.45 (-0.74), BAC: 16.04 (+0.03)

2 Small Biotech Stocks Dreaming Big in Hepatitis C
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Feb 14, 10:03AM CST
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to...
JNJ: 102.34 (-0.88), VRTX: 123.52 (+3.35), ISIS: 68.66 (+1.86), ALNY: 106.91 (+1.51), GILD: 102.79 (-1.04), ACHN: 12.14 (-0.21), SHPG: 238.90 (+2.48), MRK: 58.34 (-0.24), CVS: 103.45 (-0.74), ABBV: 59.62 (-0.84), RGLS: 18.29 (-0.28)

The 10 Most Overpaid CEOs Running Multi-Billion Dollar Companies
at The Street - Fri Feb 13, 8:22AM CST
Which CEOs have the most egregious pay packages?
VIA: 71.94 (+0.86), MCK: 227.69 (-0.53), NBR: 12.61 (+0.07), FCX: 20.99 (-0.14), DISCA: 33.99 (+1.34), DIS: 106.35 (+0.46), CVS: 103.45 (-0.74), REGN: 412.50 (-5.94), ORCL: 43.38 (-0.65), CBS: 62.80 (+1.05)

5 Things CVS Health's Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Fri Feb 13, 6:02AM CST
Make it three in a row for CVS Health ! The large pharmacy retailer and pharmacy benefits manager beat earnings expectations for the third consecutive quarter when it announced fourth-quarter results on Tuesday. Company executives discussed those...
GILD: 102.79 (-1.04), CVS: 103.45 (-0.74)

CVS Health: Still A Buy At All-Time Highs?
Josh Arnold - at Seeking Alpha - Fri Feb 13, 5:52AM CST

CVS: 103.45 (-0.74)

Rite Aid (RAD) Jumps 6.6% on TPG's EnvisionRx Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 10:40AM CST
Rite Aid (RAD) announced that it has penned a deal with EnvisionRx, to buy the latter for roughly $2 billion.
ESRX: 84.35 (-0.58), WBA: 83.21 (-0.41), CVS: 103.45 (-0.74), RAD: 8.10 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...